Skip to main content

Emergent BioSolutions moves closer to facility approval for anthrax vaccine

Emergent BioSolutions cleared a hurdle toward receiving FDA approval for a large-scale facility for making BioThrax, a vaccine for pre-exposure protection against anthrax.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.